Synthesis and pairing properties of oligoribonucleotide analogues containing a metal-binding site attached to β-d-allofuranosyl cytosine by Wu, Xiaolin & Pitsch, Stefan
 1998 Oxford University Press 4315–4323Nucleic Acids Research, 1998, Vol. 26, No. 19
Synthesis and pairing properties of oligoribonucleotide
analogues containing a metal-binding site attached to
β-D-allofuranosyl cytosine
Xiaolin Wu and Stefan Pitsch*
Organisch-Chemisches Laboratorium der Eidgenössischen Technischen Hochschule, Universitätstrasse 16,
CH-8092 Zürich, Switzerland
Received July 22, 1998; Revised and Accepted August 18, 1998
ABSTRACT
A method for the facile preparation of oligoribo-
nucleotide analogues containing β-D-allofuranosyl
nucleosides with additional functional groups tethered
to the 6′-O positions is presented. It is based on the
synthesis of two protected nucleosides carrying a
6′-O-bromopentyl and a 6′-O-methylaminopentyl
substituent. By a simple two-step procedure, these key
intermediates were transformed into two phosphor-
amidites carrying a 1-aza-18-crown-6 and a triethyl-
eneglycol group, respectively, each capable of
complexing metal ions. By automated synthesis, these
functionalized nucleoside analogues were efficiently
incorporated into short oligoribonucleotides. Under
physiological conditions (150 mM NaCl, 2 mM MgCl2,
pH 7.4), incorporation of a single allofuranosyl cytosine
substituted with a triethyleneglycol moiety led to a
significant enthalpic stabilization of an A-type RNA
duplex. This observation is in agreement with a metal
ion-mediated stabilizing interaction between the two
pairing strands.
INTRODUCTION
Modified and functionalized oligonucleotides play an important
role as molecular tools and potential antisense drugs (1).
Furthermore, there exists an as yet unexploited potential for
catalysis of chemical reactions with tailored ribozymes containing
additional side chains (2). So far, oligonucleotides have been
functionalized at the nucleobases, at the 5′- or 3′-termini, at the
phosphodiester linkages or at the 2′-O position (for recent
examples see 3–6).
During our ongoing investigations of the properties of hexo-
furanosyl oligonucleotides we developed a method for the
synthesis of oligoribonucleotides containing 6′-O-substituted
β-D-allofuranosyl and β-L-talofuranosyl nucleosides, which can
be regarded as C(5′)-substituted ribonucleosides. Preliminary
melting curve studies revealed that single incorporations of
D-allofuranosyl nucleosides in an A-type RNA duplex did not
significantly change the pairing properties (relative to those of the
parent duplex), whereas incorporation of [the C(5′)-epimeric]
L-talofuranosyl nucleosides resulted in substantial weakening of
the duplex (7; X.Wu, unpublished results).
Here we present a synthesis of the two β-D-allofuranosyl cytosine
building blocks 9 and 13, containing all protecting groups required
for automated synthesis and a 6′-O-bromopentyl (electrophilic) or a
6′-O-methylaminopentyl (nucleophilic) substituent, respectively.
The 2′-O positions were protected with the Pri3SiOCH2 (TOM)
group, which we recently introduced for the chemical synthesis
of oligoribonucleotides under standard DNA coupling conditions
(8; S.Pitsch, X.Wu, P.A.Weiss, S.Vonhoff and L.Jenny, in
preparation).
The two reactive building blocks 9 and 13 potentially serve as
starting materials for a variety of functionalized oligoribonucleotide
analogues, allowing the straightforward introduction of different
side chains at a very late stage of monomer synthesis. As first
examples, we functionalized them with two metal chelating
moieties and transformed them into phosphoramidites 15 and 17.
Preliminary molecular model studies indicated the possibility of
an interaction between a tethered metal complex (covalently
bound to the 6′-O position of an allofuranosyl nucleoside) and the
phosphodiester backbone of an unmodified partner strand across the
major groove. When an appropriate alignment is realized, such an
interaction can potentially stabilize the duplex electrostatically or
catalyse a specific strand scission reaction by providing a
correctly positioned Lewis acid. Triethyleneglycol and
1-aza-18-crown-6 were chosen as ligands for their known ability
to form complexes with the biologically abundant metal ions Na+,
K+, Mg2+ and Ca2+ (9,10).
RESULTS
Synthesis of monomers
For synthesis of the key intermediates 9 and 13 we first prepared
the appropriately pre-functionalized sugar building blocks 3 and
4 which allowed an efficient, stepwise introduction of the
nucleobase, the dimethoxytrityl group and the 2′-O protecting
group (Scheme 1).
Selective alkylation of the primary hydroxy group in diol 1 (11)
with 1,5-dibromopentane gave bromide 2 in good yields. This
reaction was accomplished by first forming the cyclic dibutyl tin-
derivative, followed by alkylation in the presence of tetrabutyl-
ammonium iodide and caesium fluoride according to Nagashima
and Ohno (12). The common precursor 2 could be elaborated by a
series of reactions into sugar building blocks 3 and 4 without
intermediate purification. The bromopentyl sugar 3 was obtained by
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Scheme 1. Reagents and conditions. (a) (i) Bu2SnO, toluene, reflux, (ii) Br(CH2)5Br, CsF, Bu4NI, DMF, room temperature. (b) For 3: (i) Pri3Si–OTf, Et(Pri)2N,
CH2Cl2, room temperature, (ii) CF3COOH, H2O, room temperature, (iii) BzCl, DMAP, py, CH2Cl2, room temperature; for 4: (i) Pri3Si–OTf, Et(Pri)2N, CH2Cl2,
room temperature, (ii) MeNH2, EtOH, room temperature, (iii) AllOC(O)Cl, Et(Pri)2N, CH2Cl2, room temperature, (iv) CF3COOH, H2O, room temperature, (v)
BzCl, DMAP, py, CH2Cl2, room temperature. (c) (i) Bis(trimethylsilyl)acetamide, N4–benzoylcytosine, MeCN, 70°C, then Me3Si–OTf, (ii) HF, HCl, MeCN, room
temperature; (d) (i) DMT–Cl, AgNO3, sym–collidine, CH2Cl2, room temperature, (ii) NaOH, THF/MeOH/H2O, 4°C. (e) Bu2SnCl2, Pri3Si–OCH2Cl, Et(Pri)2N,
(CH2Cl)2, 70°C. (f) Pd(PPh3)4, Et2NH, PPh3, CH2Cl2, room temperature.
Scheme 2. Reagents and conditions. (a) 1-aza-18-crown-6, Bu4NI, Et(Pri)2N, EtOH, 75°C. (b) (2-cyanoethyl)(N,N-diisopropylamino)-chlorophosphite,
Et(Pri)2N, CH2Cl2, room temperature. (c) Me(OCH2CH2)3Cl, Bu4NI, Et(Pri)2N, toluene, 95°C.
silylation of 2 with triisopropylsilyl triflate, cleavage of the ketal
group with 50% trifluoroacetic acid and dibenzoylation with
benzoyl chloride. The N-allyloxycarbonyl-protected methylamino-
pentyl sugar 4 was obtained by silylation of 2 with triisopropylsilyl
triflate, substitution of bromide (and cleavage of the 3-O-benzoyl
group) with methylamine, selective N-acylation with allyl
chloroformate, cleavage of the ketal group and perbenzoylation.
Nucleosidation of 3 and 4 was achieved under Vorbrüggen
conditions (13) with in situ trimethylsilylated N4-benzoylcytosine
using trimethylsilyl triflate (with 3 and 4) or SnCl4 (with 3) as
Lewis acid. Without isolation of the nucleosidation products the
Pri3Si groups were removed with a mixture of aqueous HF and
HCl in MeCN and nucleosides 5 and 6 were isolated in good
yields. From these the dimethoxytritylated diols 7 and 8 were
obtained in excellent yields by treatment with dimethoxytrityl
chloride in the presence of collidine and AgNO3 according to
Hakimelahi et al. (14), directly followed by O-debenzoylation.
Regioselective introduction of the Pri3SiOCH2 (TOM) group
at the 2′-O positions of diols 7 and 8 was carried out under
conditions developed in our laboratory (11; S.Pitsch, X.Wu,
P.A.Weiss, S.Vonhoff and L.Jenny, in preparation) and gave
compounds 9 and 11 in satisfactory yields. The 3′-O-alkylated
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Figure 1. Structure of TOM-protected phosphoramidites (TOM, triisopropylsilyl-
oxymethyl).
Figure 2. Pictures of modified A-type RNA duplexes, illustrating the position
of the additional substituents present in functionalized allofuranosyl nucleosides.
(a) The internally functionalized duplexes C.A and E.A; (b) the externally
substituted duplexes D.A and F.A. Potentially, the functional group attached to
oligonucleotides C and E can reach over the major groove and interact with the
other strand (as indicated by the arrow). The RNA duplex was constructed with
MacroModel and the substituents were added without further minimization.
regioisomers 10 and 12 were isolated as minor products. Both
pairs of regioisomers were unambigously identified by their 1H
NMR spectra according to Pitsch (11). From 11 the free methyl
aminopentyl nucleoside 13 was obtained according to Hayakawa
et al. (15).
Functionalization
Reaction of the bromopentyl-substituted nucleoside 9 and
1-aza-6-crown-18 led to the corresponding crown ether-substituted
nucleoside. During this reaction partial loss of the benzoyl
base-protecting group was observed. Therefore, it was completely
removed with ammonia, protected again with Ac2O and isolated
as the N4-acetylcytosine derivative 14 in fair yield. Under
standard conditions, it was finally transformed into phosphoramidite
15 (Scheme 2).
Reaction of the methyl aminopentyl nucleoside 13 and
diethyleneglycol monomethyl monochloroethyl diether
CH3(OCH2CH2)3Cl led to the corresponding triethyleneglycol-
substituted nucleoside 16, which was finally transformed into
phosphoramidite 17 (Scheme 2).
Synthesis of oligonucleotides
For our initial hybridization studies we designed a non-self-
complementary tetradecamer RNA sequence in which we
incorporated phosphoramidites 15 and 17 at two different
positions, one near the 3′- and one near the 5′-end (Table 1 and
Fig. 2). The syntheses were carried out on a 1.5 µmol scale using the
conditions in Table 1. Phosphoramidites 15 and 17 were efficiently
incorporated (coupling yield >98%) using twice the coupling time
required for standard, TOM-protected phosphoramidites (Fig. 1).
The removal of base and phosphate protecting groups and
cleavage from the solid support was carried out with 10 M
MeNH2 in EtOH/H2O 1:1 at 25C for 2 h. After evaporation,
complete removal of all TOM protecting groups was achieved
with 1 M Bu4NF.3H2O in THF at 25C for 12 h. After work-up
and desalting on Sephadex G-10, the sequences were purified by
reversed phase HPLC and characterized by MALDI-TOF mass
spectrometry according to Pieles et al. (16) (Table 1).
Table 1. The oligonucleotides were prepared under the
following conditions
Detritylation with 4% dichloroacetic acid, 1.2 min for TOM-
protected phosphoramidites, 2 min for 15 and 17; coupling
catalysed by 5-benzylthio-1H-tetrazole (0.25 M × 360 µl), 2.5 min
for TOM-protected phosphoramidites (0.1 M × 120 µl), 5 min for
15 and 17 (0.12 M × 120 µl); capping, Ac2O/2,6-lutidine/THF
(1:1:8), N-methylimidazole (16% v/v) in THF (1:1) 2 min;
oxidation, I2/H2O/pyridine/THF (3:2:20:75) 0.5 min.
Pairing properties
Figure 2 illustrates the position of the metal-binding sites within
duplexes formed by the functionalized tetradecamers C–F and the
corresponding complementary sequence A. When the modified
nucleosides are near the 3′-end of the sequence (Fig. 2a), they
were located in the center of the duplex and the tethered
functional groups could reach over the major groove to interact
with the backbone of the other strand (duplexes C.A and E.A,
which are internally functionalized). When the modified nucleosides
are near the 5′-end of the sequence (Fig. 2b), the functional groups
were located outside the duplex and not able to reach the other strand
(duplexes D.A and F.A, which are externally functionalized).
We expected that an eventual positive interaction between the
two pairing strands would lead to stabilization of the internally
functionalized duplexes, but not of the externally functionalized
ones. Therefore, the latter were prepared and investigated as
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Table 2. Data obtained from measurements in 10 mM Tris–HCl (pH 7.4) and 150 mM NaCl, 150 mM
KCl or 150 mM NaCl + 2 mM MgCl2
The thermodynamic data were extracted from concentration-dependent transition curves according to Marky and
Breslauer (17). The ∆∆G37C values are relative to the change in free energy of the parent duplex B.A.
reference compounds to detect intrinsic contributions which are
not the result of a specific interaction across the major groove.
Initially, two sets of exploratory experiments were carried out.
In the first set, the transition temperatures of all duplexes were
determined at pH 7.4, varying the concentrations of NaCl, KCl
and NaCl + MgCl2. In the second set, transition temperatures
were determined in 150 mM NaCl + 2 mM MgCl2, varying the
pH values from 5 to 9. These measurements revealed no
significant differences among the relative duplex stabilities
within the covered range of conditions. Further investigations
were therefore performed under physiological conditions.
The thermodynamic stability of each duplex was determined at
pH 7.4 in the presence of 150 mM NaCl, 150 mM KCl and 150 mM
NaCl + 2 mM MgCl2. The results in Table 2 were obtained from
concentration-dependent transition temperatures according to the
method developed by Marky and Breslauer (17), which allows
the determination of ∆H and ∆S for the pairing process. From
these parameters the ∆G of duplex formation at a given
temperature is calculated according to ∆G(T) = ∆H – T∆S.
The transition temperatures (‘melting points’) of the duplexes
formed from the functionalized oligoribonucleotides C, D, E and
F and the complementary partner strand A were always lower
than those of the corresponding unmodified duplex B.A. Usually,
lower transition temperatures are taken as an indication of weaker
pairing. However, determination of the ∆G values of duplex
formation revealed that at a physiologically relevant temperature
of 37C some of the functionalized oligonucleotides were in fact
more strongly paired than the parent one (Table 2 and Fig. 3).
The thermodynamic data for the crown ether-containing RNA
strands in both NaCl and KCl solution at 37C revealed a less
favourable ∆G for the internally functionalized duplex C.A than
for the externally functionalized duplex D.A. In KCl solution the
duplex C.A showed a weaker pairing than the unmodified duplex
B.A, whereas in NaCl both sequences displayed about the same
∆G value. In the presence of 2 mM MgCl2, however, the duplex
C.A displayed a stronger pairing than the duplex D.A and than the
parent duplex B.A. The more negative ∆G value of duplex
formation for the functionalized duplex C.A (relative to the parent
duplex B.A) is the consequence of a more favourable ∆H term,
which below 50C compensates for the less favourable ∆S term
(Fig. 3).
The ∆G values of duplex formation at 37C obtained from
pairing of the triethyleneglycol-substituted oligoribonucleotides
E.A and F.A indicate a stronger association of sequence E
compared with sequence F in all three environments investigated.
In KCl and NaCl solution the difference in ∆G37C values was
about –3 kcal/mol in favour of the internally functionalized duplex
E.A. In the presence of 2 mM MgCl2, however, a very large energy
difference of –8 kcal/mol (35% of total at 37C), again in favour of
sequence E, was observed. The externally functionalized duplex F.A
uniformly displayed a weaker pairing than the unmodified duplex
B.A, whereas the internally functionalized duplex E.A showed an
equal pairing in KCl (–0.3 kcal/mol), a slightly stronger pairing
in NaCl (–2.3 kcal/mol) and a much stronger pairing in NaCl +
MgCl2 (–6.5 kcal/mol) than the unmodified duplex B.A. Again,
the strong stabilization of the functionalized duplex E.A (relative
to the unfunctionalized duplex B.A) is a consequence of a more
favourable ∆H term which below 65C compensates for the less
favourable ∆S term (Fig. 3).
DISCUSSION
These thermodynamic data for duplex stability indicate that in the
presence of Mg2+ ions pairing is slightly stabilized by a
1-aza-18-crown-6 group and strongly stabilized by a triethylene-
glycol group tethered to the 6′-O position of an allofuranosyl
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Figure 3. A comparison of the temperature dependance of ∆G values among
the parent duplex B.A, the crown ether-substituted duplexes C.A and D.A (a)
and the triethylenglycol-substituted duplexes E.A and F.A (b). Data were
obtained from concentration-dependant transition curves measured in 150 mM
NaCl + 2 mM MgCl2, 10 mM Tris–HCl (pH 7.4).
nucleoside. In the absence of Mg2+ ions only the triethyleneglycol-
substituted duplex is slightly stabilized.
Structurally, these observations indicate a specific interaction
of the Mg2+-complexed ligand of the modified nucleosides with
the negatively charged backbone of the other strand. The open
chain ligand present in oligonucleotide E forms a relatively weak
complex with the Mg2+ ion, still offering additional coordination
sites. It was concluded that the strong duplex stabilization
observed results from formation of a complex between the
ethyleneglycol moiety, a Mg2+ ion and a phosphodiester group of
the partner strand A. Thereby, one hydrated Mg2+ ion within the
major groove is replaced by a chelated Mg2+ ion (Fig. 4). The
cyclic ligand present in oligonucleotide C forms a very strong
complex with the Mg2+ ion and no additional coordination to the
phosphodiester backbone is possible. The weak duplex stabilization
observed is concluded to be the result of an electrostatic interaction
between the positively charged Mg2+ complex and the negatively
charged phosphodiester backbone of the partner strand.
The additional non-covalent intramolecular interactions were
reflected in the enthalpic stabilization of duplexes C.A and E.A.
On the other hand, the conformational changes within the tethered
group and/or the backbone required for such an interaction led to
an entropic destabilization, which compensated largely, but at low
temperature not entirely, for the enthalpic stabilization. In all cases
where no stabilization of the duplex could be observed no significant
differences in enthalpy and entropy terms were measured, indicating
that the additional functional group was pointing into the solution.
We were unable to detect any structural changes upon introduction
of the functionalized allofuranosyl cytidines into RNA strands by
Figure 4. Model representation (MacroModel) of the metal ion-mediated
interaction between the two strands of the functionalized duplexes C.A and E.A
as deduced from the thermodynamic data of duplex formation. For the sake of
clarity, only the relevant part of the duplex is shown; the atoms of the
phosphodiester backbones and the bonds of the functional group are in black.
CD spectroscopy. All duplexes essentially had the same CD
spectrum, typical for an A-type RNA duplex.
CONCLUSION AND OUTLOOK
The strategy presented here allows a straightforward preparation
of a variety of functionalized oligonucleotides and revealed the
5′-position of nucleosides as a new and promising site for
modification, labelling and conjugate formation. The metal-binding
derivatives which have been prepared as first examples constitute
a new principle for stabilizing oligonucleotide duplexes. We now
are preparing reactive allofuranosyl and 2′-deoxyallofuranosyl
nucleosides with the other three nucleobases and with different
tethers. We will also determine whether 5′-triphosphates derived
from those can be incorporated enzymatically into DNA or RNA.
Employing nucleotide analogues related to those presented in this
paper, we are trying to find oligoribo- and oligodeoxyribonucleotide
analogues eventually capable of stabilizing RNA and/or DNA
structure, catalysing specific strand scission reactions and
enhancing cellular uptake.
MATERIALS AND METHODS
General
Work-up implies distribution of the reaction mixture between
CH2Cl2 and saturated aqueous NaHCO3 solution, drying of the
organic layer with MgSO4, filtration and evaporation of the filtrate.
TLC: unless otherwise mentioned, precoated silica gel plates from
Macherey & Nagel (exceptionally pre-coated Al2O3 plates from
Merck), stained by dipping into a solution of 10 ml anisaldehyde,
10 ml concentrated H2SO4, 2 ml AcOH in 180 ml EtOH and
subsequent heating with a heat gun. Column chromatography (CC):
unless otherwise mentioned, silica gel 60 (230–400 mesh) from
Fluka (exceptionally Al2O3, activity III, from ICN Adsorbentien).
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Optical rotation ([α] 25D ): Jasco-DIP-370, all measurements in
CHCl3 (1 g/100 ml). UV spectra: Uvikon 931, λmax in nm, ε
(dm3/mol/cm) indicated in parentheses, all measurements in
MeOH. NMR: Varian-Gemini 300 (1H, 300 MHz; 31P, 121 MHz),
chemical shift δΗ in p.p.m. (Me4Si as internal standard), δP in
p.p.m. (85% H3PO4 as external standard), all measurements in
CDCl3, coupling constants J in Hz. MS: VG-ZAB2-SEQ, all
samples measured in FAB+ mode, 3-nitrobenzyl alcohol as
matrix, relative intensity in % as indicated in parentheses.
Oligonucleotide synthesis
The oligoribonucleotides were assembled on CPG supports
(1.5 µmol scale) on a Pharmacia Gene Assembler using the
methods in Table 1. The TOM-protected phosphoramidites and
solid supports were from Xeragon AG (Switzerland). Average
coupling yields were >99% (detritylation assay). Deprotection
was carried out as described in the text. The crude product was
purified by reversed phase HPLC and finally desalted according
to Pitsch (11).
Thermal denaturation studies
Absorbance versus temperature profiles were recorded in fused
quartz cuvettes at 260 nm on a Cary Bio-1 spectrophotometer
equipped with a Peltier temperature control device. The samples
were prepared under sterile conditions from stock solutions of the
oligonucleotide, 1 M Tris–HCl buffer (pH 7.4) and 5 M NaCl
solution and subsequently degassed. A layer of silicon oil was
placed on the surface of the solution. The studies were carried out
at 0.5, 1, 2, 4 and 8 µM concentrations of both strands. Prior to
the measurements, each sample was briefly heated to 80C. The
curves were obtained with both a cooling and heating ramp of
0.3C/min.
The transition temperatures were obtained after differentiation
of the melting curves and analysed according to Marky and
Breslauer (17).
3-O-Benzoyl-6-O-(5-bromopentyl)-1,2-O-isopropyliden-α-D-
allofuranose (2)
In a Dean-Stark apparatus, a solution of 3-O-benzoyl-1,2-O-iso-
propylidene-α-D-allofuranose (1) (11) (9.72 g, 30 mmol) and
Bu2SnO (11.2 g, 33 mmol) in toluene (75 ml) was refluxed for
1 h. The toluene was evaporated, the residue diluted with DMF
(75 ml) and treated with CsF (6.84 g, 45 mmol), 1,5-dibromopentane
(16.3 ml, 120 mmol) and Bu4NI (16.62 g, 45 mmol). The
suspension was kept at room temperature for 8 h. Work-up and
CC (hexane/EtOAc 9:1–6:4) gave 2 (9.4 g, 74%) as a colourless,
viscous liquid. TLC (hexane/EtOAc 1:1) 0.64; [α] 25D  +28.0; δH
1.33 (s, Me), 1.41–1.49 (m, CH2), 1.54 (s, Me), 1.58–1.61
(m, CH2), 1.81–1.85 (m, CH2), 2.46 (d, J 3.7, 5-OH), 3.37 (t, J 6.8,
CH2), 3.40–3.50 (3 H, m, CH2O, H,H′-6), 4.12 (m, H-5), 4.36
(dd, J 3.7, 8.4, H-4), 4.97 (dd, J 3.7, 5.0, H-2), 5.15 (dd, J 5.0, 8.4,
H-3), 5.89 (d, J 3.7, H-1), 7.46 (m, 2 ArH), 7.59 (m, 1 ArH); 8.06
(m, 2 ArH); m/z 474 (1, MH+), 104 (100).
6-O-(5-bromopentyl)-1,2,3-O-tribenzoyl-5-O-[(triisopropyl)-
silyl]-α,β-D-allofuranose [3(α/β)]
At room temperature, a solution of 2 (3.52 g, 7.4 mmol) in
CH2Cl2 (25 ml) was treated with Pri2NEt (3.8 ml, 22.2 mmol) and
Pri3SiOSO2CF3 (2.6 ml, 9.7 mmol) for 1 h. After work-up, the
crude product was treated with CF3COOH (50 ml) and H2O
(50 ml) for 2 h. Work-up gave a colourless oil, which was
dissolved in pyridine (3 ml) and CH2Cl2 (6 ml) and treated with
benzoyl chloride (1.5 ml, 13 mmol) and dimethylamino pyridine
(82 mg, 0.67 mmol) for 12 h. Work-up and CC (hexane/EtOAc
9:1–7:3) gave 3a(α/β) (4.7 g, 54%, α/β 1:2 by NMR) as a
colourless foam. TLC (hexane/EtOAc 4:1) 0.66; δH 0.66–1.15
(21 H, m, Pri3Si), 1.33–1.53 (m, 2 CH2), 1.65–1.82 (m, CH2),
3.21–3.24 (m, H-6), 3.34–3.46 (3 H, m, H′-6, CH2), 3.50–3.62
(m, CH2), 4.30 [m, H–C(5)], 4.67 [dd, J 4.4, 5.6, H-4(α)], 4.97
[m, H-4(β)], 5.60 [dd, J 4.4, 6.5, H-2(β)], 5.90 [dd, J 2.2, 5.3,
H-2(α)], 6.03 [dd, J 5.3, 5.5, H-3(α)], 6.09 [dd, J 1.9, 6.5,
H-3(β)], 6.61 [d, J 2.2, H-1(α)], 6.87 [d, J 4.4, H-1(β)], 7.17–7.61
(m, 9 ArH), 7.76–8.10 (m, 6 ArH); m/z 801 (6, MH+).
N4-Benzoyl-1-[6′-O-(5-bromopentyl)-2′,3′-di-O-benzoyl-β-D-
allofuranosyl]cytosine (5)
A suspension of 3(α/β) (5.4 g, 6.75 mmol), N4-benzoylcytosine
(18) (1.6 g, 7.4 mmol) and bis(trimethylsilyl)acetamide (4.2 ml,
16.9 mmol) in CH3CN (27 ml) was stirred at 70C for 1 h, treated
with SnCl4 (3.2 ml, 27 mmol) and stirred at 70C for 20 min.
After work-up, the residue was dissolved in CH3CN (200 ml),
treated with HCl (conc.) (2 ml) and HF (40% in H2O) (4 ml) and
stirred at room temperature for 8 h. Work-up and CC (hexane/
EtOAc 8:2–4:6) gave 5 (3.6 g, 71%) as a white foam. TLC
(hexane/EtOAc 2:8) 0.55; [α] 25D  –97.2; λmax 261 (21 000), 229
(28 900); δH 1.44–1.64 (4 H, m, 2 CH2), 1.75–1.90 (m, CH2),
3.37 (t, J 6.8, CH2), 3.48–3.53 (m, 2 H-6′), 3.65–3.67 (3 H, m,
OCH2, OH-5′), 4.30 (m, H-5′), 4.45–4.49 [m, H–C(4′)], 5.88
(dd, J 5.6, 6.6, H-2′), 5.99 (dd, J 2.5, 5.6, H-3′), 6.58 (d, J 6.8,
H-1′), 7.26–8.03 (m, 15 ArH, H-5), 8.35 (d, J 7.8, H-6), 8.77
(s, NH); m/z 736 (11, M+).
N4-Benzoyl-1-[6′-O-(5-bromopentyl)-5′-O-(4,4′-dimethoxy-
trityl)-β-D-allofuranosyl]cytosine (7)
A suspension of 5 (2.7 g, 3.6 mmol), AgNO3 (612 mg, 3.6 mmol)
and sym-collidine (1.2 ml, 9 mmol) in CH2Cl2 (12 ml) was treated
with 4,4′-dimethoxytrityl chloride (1.84 g, 5.4 mmol) for 1 h at
room temperature. After filtration and evaporation, the residue
was dissolved in an ice-cold solution of THF/MeOH/H2O 5:4:1
(150 ml), treated with 10 N aqueous NaOH (3 ml) at 4C for
15 min, then neutralized with AcOH (1.9 ml) and concentrated to
40 ml. Work-up and CC [CH2Cl2 to CH2Cl2/MeOH 97:3 (+2%
NEt3)] gave 7 (2.46 g, 84%) as a white foam. TLC (MeOH/
CH2Cl2 8:92) 0.50; [α] 25D  +28.4; λmax 262 (14 700), 238 (22 300);
δH 1.44–1.63 (m, 2 CH2), 1.80–1.92 (m, CH2), 3.19–3.27
(m, OCH2, H-6′), 3.42 (t, J 6.5, CH2), 3.40–3.45 (m, H′-6′),
3.55–3.64 (m, H-5′, OH), 3.80 (s, 2 OMe), 4.21–4.27 (m, H-2′,
H-4′), 4.44 (s, OH), 4.67 (dd, J 5.6, 5.8, H-3′), 5.86
(d, J 3.1, H-1′), 6.82–6.86 (m, 4 ArH), 7.22–7.63 (m, 12 ArH,
H-5), 7.88–7.89 (m, 2 ArH), 7.92 (d, J 7.5, H-6), 8.88 (s, NH); m/z
829 (18, MH+), 303 (100).
N4-Benzoyl-1-[6′-O-(5-bromopentyl)-5′-O-(4,4′-dimethoxy-
trityl)-2′-O-{[(triisopropyl)silyloxy]methyl}-β-D-allofurano-
syl]cytosine (9)
A solution of 7 (2.46 g, 3.0 mmol) and Pri2NEt (2.1 ml, 12 mmol)
in ClCH2CH2Cl (10 ml) was treated with Bu2SnCl2 (1.1 g,
4321
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3.6 mmol) at room temperature for 1.5 h, then treated with
Pri3SiOCH2Cl (1.0 g, 4.5 mmol) at 80C for 15 min. Work-up
and CC [hexane/EtOAc 5:5–2:8 (+ 2% NEt3)] gave 9 (1.28 g,
42%) and 10 (570 mg, 20%) as pale yellow foams. TLC
(hexane/EtOAc 3:7) 0.63; [α] 25D  +36.8; λmax 260 (17 800), 238
(23 800); δH 1.08–1.22 (21 H, m, Pri3Si), 1.41–1.49 (m, 2 CH2),
1.81–1.86 (m, CH2), 3.15–3.22 (m, H-6′, CH2O), 3.39 (t, J 6.9,
CH2), 3.50–3.55 (m, OH, H′-6′), 3.67 (s, H-5′), 3.81 (s, 2 OMe),
4.15–4.20 (m, H-2′, H-4′), 4.63 (dd, J 5.4, 6.4, H-3′), 5.11 and
5.23 (2d, J 4.7, OCH2O), 6.01 (d, J 2.8, H-1′), 6.84–6.87
(m, 4 ArH), 7.25–7.61 (m, 12 ArH, H-5), 7.79–7.88 (m, 2 ArH),
7.89 (d, J 7.8, H-6), 8.61 (s, NH); m/z 1016 (100, MH+).
N4-Benzoyl-1-[6′-O-(5-bromopentyl)-5′-O-(4,4′-dimethoxy-
trityl)-3′-O-{[(triisopropyl)silyloxy]methyl}-β-D-allofuranosyl]-
cytosine (10)
From the reaction described above. TLC (hexane/EtOAc 3:7)
0.35; [α] 25D  –11.4; δH 1.08–1.11 (21 H, m, Pri3Si), 1.39–1.48
(m, 2 CH2), 1.81–1.86 (m, CH2), 3.13–3.21 (m, H-6′, OCH2),
3.40 (t, J 6.8, CH2), 3.37–3.42 (m, H′-6′), 3.50 (s, H-5′), 3.80
(s, 2 OMe), 3.77–3.84 (m, OH-2′), 4.12 (m, H-2′), 4.32 (m, H-4′),
4.65 (dd, J 3.4, 5.6, H-3′), 4.98 and 5.17 (2d, J 4.8, OCH2O), 5.96
(d, J 6.2, H-1′), 6.83–6.85 (m, 4 ArH), 7.23–7.62 (m, 14 ArH,
H-5), 7.90 (d, J 7.2, H-6), 8.61 (s, NH); m/z 1016 (54, MH+), 303
(100).
N4-Acetyl-1-{6′-O-[5-(1,4,7,10,13-pentaoxa-16-aza-cyclo-
octadec-16-yl)-pentyl]-5′-O-(4,4′-dimethoxytrityl)-2′-O-
{[(triisopropyl)silyloxy]methyl}-β-D-allofuranosyl}cytosine (14)
A solution of 9 (408 mg, 0.4 mmol), 1-aza-18-crown-6 (263 mg,
1.0 mmol), Pri2NEt (0.34 ml, 2 mmol) and Bu4NI (222 mg,
0.6 mmol) in EtOH (1 ml) was stirred at 75C for 30 h. After
work-up, the residue was treated with NH3 in EtOH/H2O 9:1
(2 ml) at room temperature for 10 h. Evaporation and filtration
through a short Al2O3 column (CH2Cl2/MeOH 9:1) gave a
product (277 mg, 0.25 mmol) which was dissolved in DMF (1 ml)
and treated with Ac2O (31 µl, 0.32 mmol). After stirring for 4 h
at room temperature, work-up and CC (Al2O3, CH2Cl2 to
MeOH/CH2Cl2 3:97) 14 (192 mg, 43%) was obtained as a yellow
foam. TLC (Al2O3, MeOH-CH2Cl2 4:96) 0.42; [α] 25D  +19.9; λmax
261 (19 900), 238 (23 600); δH 1.06–1.09 (21 H, m, Pri3Si),
1.20–1.28 (m, CH2), 1.37–1.49 (m, 2 CH2), 2.21 (s, MeCO), 2.46
(t, J 7.5, CH2), 2.74 (t, J 5.9, 4 CH2), 3.12–3.19 (m, H-6′, CH2O),
3.45–3.50 (dd, J 6.5, 10.5, H′-6′), 3.58–3.67 (22 H, m), 3.80
(s, OMe), 4.12–4.15 (m, H-2′, H-4′), 4.60 (m, H-3′), 5.07 and 5.21
(2d, J 4.7, OCH2O), 5.98 (d, J 3.8, H-1′), 6.81–6.84 (m, 4 ArH),
7.23–7.51 (m, ArH, H-5), 7.74–7.67 (d, J 7.5, H-6), 9.18 (s, NH);
m/z 1136 (100, M+).
N4-Acetyl-1-{6′-O-[5-(1,4,7,10,13-pentaoxa-16-aza-cyclo-
octadec-16-yl)-pentyl]-5′-O-(4,4′-dimethoxytrityl)-2′-O-
{[(triisopropyl)silyloxy]methyl}-β-D-allofuranosyl}cytosine
3′-[(2-cyanoethyl) N,N-diisopropyl-phosphoramidite] (15)
A solution of 14 (192 mg, 0.17 mmol) in CH2Cl2 (0.75 ml) was
treated consecutively with Pri2NEt (73 µl, 0.43 mmol) and
(2-cyanoethyl)(N,N-diisopropylamino)chlorophosphite (48 mg,
0.20 mmol). After stirring for 1 h at room temperature, the
mixture was subjected to CC (Alox, hexane/EtOAc 6:4–3:7) and
15 (210 mg, 92%) was obtained as a pale yellow foam (1:1
mixture of diastereoisomers). TLC (Al2O3, MeOH/CH2Cl2 4:96)
0.52; λmax 239 (23 600); δH 1.00–1.07 (21 H, m, Pri3Si),
1.13–1.21 (m, 4 Me), 1.32–1.36 (m, 3 CH2), 2.21 (s, MeCO),
2.42–2.44 (m, CH2), 2.54 and 2.61 (2t, J 6.5, CH2), 2.73 (t, J 5.8,
4 CH2), 2.97–3.08 (m, OCH2, H-6′), 3.39–3.67 (25 H, m), 3.79
(s, 2 OMe), 4.27 and 4.32 (2dd, J 5.0, 5.3, H-2′), 4.40 (m, H-4′),
4.64–4.77 (m, H-3′), 4.96–5.06 (m, OCH2O), 6.05 (0.5 H, d,
J 3.7, H-1′), 6.06 (0.5 H, d, J 4.7, H-1′), 6.81–6.84 (m, 4 ArH),
7.23–7.50 (m, 10 ArH, H-5), 7.61–7.66 (m, H-6), 9.18 (s, NH);
δP 150.2, 149.8; m/z 1336 (100, M+).
6-O-[5-(N-Allyloxycarbonyl-methylamino)-pentyl]-1,2,3-tri-
O-benzoyl-5-O-[(triisopropyl)silyl]-β-D-allofuranose [4(α/β)]
At room temperature, a solution of 2 (9.78 g, 21 mmol) in CH2Cl2
(70 ml) was treated with Pri2NEt (10.8 ml, 63 mmol) and
Pri3SiOSO2CF3 (7.34 ml, 27.3 mmol) for 1 h. Work-up gave a
crude product, which was treated with MeNH2 in EtOH (8 M,
70 ml) for 1 h at room temperature. After evaporation and
work-up, the residue was dissolved in CH2Cl2 (70 ml) and treated
with Pri2NEt (7.2 ml, 42 mmol) and allyl chloroformate (2.2 ml,
21 mmol) at room temperature for 0.5 h. Work-up gave a yellow
oil. The crude product obtained by treatment of the resulting oil
with CF3COOH (50 ml) and H2O (50 ml) for 1 h at room
temperature was dissolved in pyridine (15 ml) and CH2Cl2
(30 ml) and treated with benzoyl chloride (5.6 ml, 48 mmol) and
dimethylaminopyridine (293 mg, 2.4 mmol) for 12 h. Work-up
and CC (hexane/EtOAc 9:1–7:3) gave 4(α/β) (2.5 g, 42%, α/β
1:2 by 1H NMR). TLC (hexane/EtOAc 7:3) 0.47; δH 1.05–1.15
(7 H, m, Pri3Si), 1.21 (m, CH2), 1.44 (m, 2 CH2), 2.83 (s, CH3),
3.09–3.11 (m, CH2), 3.31–3.41 (m, 2 H-6), 3.59 (d, J 5.9, CH2),
4.26 [m, H-5(α)], 4.31 [m, H-5(β)], 4.55 (m, CH2), 4.66 [dd,
J 4.3, 5.1, H-4(α)], 4.78 [dd, J 1.8, 1.9, H-4(β)], 5.23 (m, CH2),
5.60 [dd, J 4.3, 6.5, H-2(β)], 5.90 [dd, J 2.5, 5.3, H-2(α)],
5.92–5.94 (m, CH), 6.02 [dd, J 2.2, 5.3, H-3(α)], 6.08 [dd, J 1.9,
6.5, H-3(β)], 6.61 [d, J 2.1, H-1(α)], 6.87 [d, J 4.4, H-1(β)],
7.17–7.61 (m, 9 ArH), 7.75–8.12 (m, 6 ArH); m/z 833 (2, MH+),
710 (100).
N4-Benzoyl-1-{6′-O-[5-(N-allyloxycarbonyl-methylamino)-
pentyl]-2′,3′-di-O-benzoyl-β-D-allofuranosyl}cytosine (6)
As described for 5, with 4(α/β) (4.7 g, 5.7 mmol), N4-benzoyl-
cytosine (18) (1.36 g, 6.3 mmol), bis(trimethylsilyl)acetamide
(3.5 ml, 14.4 mmol), CH3CN (20 ml), Me3Si-OTf (2.7 ml,
22.8 mmol), then CH3CN (100 ml), HCl (conc.) (1 ml), HF (40%
in H2O) (2 ml). Work-up and CC (hexane/EtOAc 8:2–4:6) gave
6 (3.4 g, 74%) as a white foam. TLC (hexane/EtOAc 4:6) 0.53;
[α] 25D  –54.2; λmax 261 (26 600), 237 (30 100); δH 1.34 (m, CH2),
1.57 (m, 2 CH2), 2.89 (s, CH3), 3.26 (br. s, CH2), 3.51–3.53
(m, 2 H-6′), 3.64–3.66 (m, CH2O, OH), 4.29 (s, H-5′), 4.45
(s, H-4′), 4.57–4.59 (m, CH2), 5.25 (m, CH2), 5.83–5.97 (m, H-2′,
H-3′, CH), 6.60 (s, H-1′), 7.27–8.03 (m, 15 ArH, H-5), 8.36
(m, H-6), 8.72 (s, NH); m/z 770 (100, MH+).
N4-Benzoyl-1-{6′-O-[5-(N-allyloxycarbonyl-methylamino)-
pentyl]-5′-O-(4,4′-dimethoxytrityl)-β-D-allofuranosyl}cytosine
(8)
As described for 7, with 6 (2 g, 2.66 mmol), AgNO3 (687 mg,
4.0 mmol), sym-collidine (0.7 ml, 2 mmol), CH2Cl2 (12 ml),
4,4′-dimethoxytrityl chloride (1.36 g, 4.0 mmol), then THF/
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MeOH/H2O 5:4:1 (120 ml), 10 N aqueous NaOH (2.4 ml), AcOH
(1.5 ml). Work-up and CC [CH2Cl2 to CH2Cl2/MeOH 98:2 (+2%
NEt3)] gave 8 (2.1 g, 91%) as a white foam. TLC (MeOH/CH2Cl2
8:92) 0.54; [α] 25D  +28.3; λmax 258 (13 400), 237 (27 000); δH 1.27
(m, CH2), 1.32 (m, 2 CH2), 2.90 (s, CH3), 3.21–3.30
(m, CH2, CH2O, H-6′), 3.41 (dd, J 4.2, 10.5, H′-6′), 3.62 (s, H-5′),
3.80 (s, 2 OMe), 4.22 (m, H-2′, H-4′), 4.56 (d, J 5.3, CH2), 4.66
(m, H-3′), 5.16–5.30 (m, CH2), 5.88 (d, J 2.2, H-1′), 5.89–5.97
(m, CH), 6.82–6.85 (m, 4 ArH), 7.21–7.62 (m, 12 ArH, H-5),
7.88–7.93 (m, 2 ArH, H-6), 8.65 (s, NH); m/z 864 (28, MH+), 303
(100).
N4-Benzoyl-1-{6′-O-[5-(N-allyloxycarbonyl-methylamino)-
pentyl]-5′-O-(4,4′-dimethoxytrityl)-2′-O-{[(triisopropyl)silyl-
oxy]methyl}-β-D-allofuranosyl}cytosine (11)
As described for 9, with 8 (862 mg, 1.0 mmol), Pri2NEt (0.85 ml,
5 mmol), ClCH2CH2Cl (4 ml), Bu2SnCl2 (340 mg, 1.1 mmol),
Pri3SiOCH2Cl (230 mg, 1.2 mmol). Work-up and CC [hexane/
EtOAc 5:5–2:8 (+2% NEt3)] gave 11 (470 mg, 45%) and 12
(209 mg, 20%) as pale yellow foams. TLC (hexane/EtOAc
15:85) 0.60; [α] 25D  +29.1; λmax 260 (23 900), 238 (28 700); δH
1.07–1.14 (21 H, m, Pri3Si), 1.23 (m, CH2), 1.46–1.56
(m, 2 CH2), 2.89 (s, Me), 3.13–3.26 (m, 2 CH2, H-6′), 3.48–3.56
(m, OH, H′-6′), 3.64–3.66 (m, H-5′), 3.82 (s, 2 OMe), 4.11
(m, H-2′), 4.20 (m, H-4′), 4.56–4.67 (m, H-3′, CH2), 5.15 and
5.23 (2d, J 4.6, OCH2O), 5.17–5.31 (m, CH2), 5.88–5.97
(m, CH), 6.01 (d, J 2.3, H-1′), 6.83–6.86 (m, 4 ArH), 7.23–7.63
(m, 12 ArH, H-5), 7.87–7.89 (m, 2 ArH, H-6), 8.57 (s, NH); m/z
1050 (4, MH+), 303 (100).
N4-Benzoyl-1-{6′-O-[5-(N-allyloxycarbonyl-N-methyl)-
pentyl]-5′-O-(4,4′-dimethoxytrityl)-3′-O-{[(triisopropyl)silyl-
oxy]methyl}-β-D-allofuranosyl}cytosine (12)
Obtained from the reaction described above. TLC (hexane/
AcOEt 15:85) 0.36; [α] 25D  –7.2; λmax 260 (24 600), 238 (29 700);
δH 1.07–1.11 (21 H, m, Pri3Si), 1.20–1.26 (m, CH2), 1.42–1.64
(m, 2 CH2), 2.90 (s, CH3), 3.22–3.27 (m, NCH2, CH2O, H-6′),
3.36–3.41 (m, H′-6′), 3.48–3.50 (m, H-5′), 3.75–3.81 (m, OH-2′),
3.80 (s, 2 OMe), 4.10–4.14 (m, H-2′), 4.32 (m, H-4′), 4.56–4.58
(m, CH2), 4.65 (m, H-3′), 4.97 and 5.17 (2d, J 4.7, OCH2O),
5.20–5.31 (m, CH2), 5.89–5.98 (m, CH), 5.96 (d, J 6.2, H-1′),
6.79–6.86 (m, 4 ArH), 7.21–7.64 (m, 14 ArH, H-5), 7.90 (d, J 6.2,
H-6), 8.64 (s, NH); m/z 1059 (8, MH+), 303 (100).
N4-Benzoyl-1-{6′-O-(N-methyl-5-aminopentyl)-5′-O-(4,4′-
dimethoxytrityl)-2′-O-{[(triisopropyl)silyloxy]methyl}-β-D-
allofuranosyl}cytosine (13)
A suspension of Pd[P(Ph)3]4 (126 mg, 0.11 mmol) and PPh3
(60 mg, 0.23 mmol) in CH2Cl2 (3 ml) was added dropwise to a
solution of 11 (604 mg, 0.58 mmol) and Et2NH (0.3 ml,
2.9 mmol) in CH2Cl2 (3 ml). The solution was stirred for 1 h at
room temperature. After evaporation, the residue was subjected
to CC [CH2Cl2 to MeOH/CH2Cl2 5:95 (+ 2% Et3N)] and 13
(488 mg, 88%) was obtained as a yellow foam. TLC (Al2O3,
MeOH/CH2Cl2 4:96) 0.45; [α] 25D  +23.4; λmax 261 (19 800), 238
(25 500); δH 1.08 (21 H, m, Pri3Si), 1.29–1.37 (m, CH2),
1.44–1.51 (m, 2 CH2), 2.43 (s, NMe), 2.55 (t, J 1.2, NCH2),
3.15–3.20 (m, OCH2, H-6′), 3.48–3.56 (m, H′-6′, NH), 3.65–3.68
(m, H-5′), 3.77–3.79 (m, OH-3′), 3.81 (s, 2 OMe), 4.13–4.17
(m, H-4′), 4.21 (dd, J 3.1, 5.3, H-2′), 4.63–4.65 (m, H-3′), 5.10
and 5.22 (2 d, J 4.7, OCH2O), 5.99 (d, J 3.1, H-1′), 6.83–6.86 
m, 4 ArH), 7.25–7.63 (m, 12 ArH, H-5), 7.80–7.83 (m, 2 ArH),
7.91 (d, J 7.2, H-6); m/z 965 (100, M+).
N4-Benzoyl-1-{6′-O-(N-methyl-5-[(2-[2-methoxy-ethoxy]-
ethoxy)-ethylamino]-pentyl)-5′-O-(4,4′-dimethoxytrityl)-2′-
O-{[(triisopropyl)silyloxy]methyl}-β-D-allofuranosyl}cytosine
(16)
A solution of 13 (244 mg, 0.253 mmol), Bu4NI (187 mg,
0.506 mmol), Pri2NEt (0.17 ml, 1.0 mmol) in 0.8 ml toluene was
treated with Me(OCH2CH2)3Cl (18) (110 mg, 0.61 mmol) and
stirred for 8 h at 95C. Work-up and CC [CH2Cl2 to MeOH/
CH2Cl2 3:97 (+ 2% Et3N)] gave 16 (120 mg, 44%) as a yellow
foam. TLC (Al2O3, MeOH/CH2Cl2 3:97) 0.41; λmax 259
(19 700), 234 (28 700); δH 1.05–1.09 (21 H, m, Pri3Si), 1.26–1.29
(m, CH2), 1.32–1.39 (m, 2 CH2), 2.25 (s, NMe), 2.33–2.38
(m, NCH2), 2.55–2.59 (m, CH2), 3.14–3.21 (m, OCH2, H-6′),
3.36 (s, OMe), 3.50–3.66 (m, OH-3′, 2 CH2, H′-6′, H-5′), 3.80
(s, 2 OMe), 4.14–4.21 (m, H-2′, H-4′), 4.62–4.66 (m, H-3′), 5.13
and 5.23 (2 d, J 4.7, OCH2O), 6.01 (d, J 2.8, H-1′), 6.84–6.86
(m, 4 ArH), 7.25–7.63 (m, 12 ArH, H-5), 7.82–7.85 (m, 2 ArH),
7.88 (d, J 7.2, H-6); m/z 1113 (3, MH+), 303 (100).
N4-Benzoyl-1-{6′-O-(N-methyl-5-[(2-[2-methoxy-ethoxy]-
ethoxy)-ethylamino]-pentyl)-5′-O-(4,4′-dimethoxytrityl)-
2′-O-{[(triisopropyl)silyloxy]methyl}-β-D-allofuranosyl}cytosine
3′-[(2-cyanoethyl) N,N-diisopropyl-phosphoramidite] (17)
As described for 15, with 16 (120 mg, 0.11 mmol), CH2Cl2
(0.3 ml), Pri2NEt (47 µl, 0.28 mmol) and (2-cyanoethyl)(N,N-
diisopropylamino)chlorophosphite (31 mg, 0.12 mmol). CC
(Al2O3, hexane/AcOEt 6:4–2:8) gave 17 (130 mg, 90%) as a pale
yellow foam (1:1 mixture of diastereoisomers). TLC (Al2O3,
MeOH/CH2Cl2 4:96) 0.52; λmax 261 (18 700), 239 (27 700); δH
1.02–1.08 (21 H, m, Pri3Si), 1.16–1.25 (m, 4 Me), 1.26–1.28
(m, CH2), 1.34–1.39 (m, 2 CH2), 2.24 (s, NMe), 2.31–2.34
(m, NCH2), 2.54–2.63 (m, 2 CH2), 2.92–3.08 (m, OCH2, H-6′),
3.36 and 3.37 (2s, CH3), 3.43–3.62 (m, 12 H, 2 CH2, H′-6′, H-5′),
3.80 (s, 2 OMe), 4.20–4.41 (m, H-2′, H-4′), 4.66–4.69 (m, 0.5 H,
H-3′), 4.75–4.79 (m, 0.5 H, H-3′), 5.00–5.05 (m, OCH2O), 6.07
and 6.09 (2 s, H-1′), 6.82–6.85 (m, 4 ArH), 7.23–7.71 (m, 12 ArH,
H-5), 7.89–7.91 (m, 2 ArH), 8.02 (d, J 7.2, H-6), 8.61 (s, NH); δP
150.2, 149.8; m/z 1313 (26, MH+), 1312 (36, M+), 303 (100).
SUPPLEMENTARY MATERIAL
The 13C NMR and IR data of compounds 2–17, the CD spectra
of all duplexes and a table of all concentration-dependant
transition temperatures are available upon request.
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